Drug Type Small molecule drug |
Synonyms EM 113 |
Target |
Mechanism NMDA receptor agonists(Glutamate [NMDA] receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Eumentis Therapeutics, Inc.Startup |
Active Organization Eumentis Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autism Spectrum Disorder | Phase 2 | US | Eumentis Therapeutics, Inc.Startup | 16 Feb 2023 |